“We are taking action to address the ESG issues most relevant to our business and our stakeholders, including climate change, diversity, pay equity, transparency and reducing the environmental impact of our products. “, said Tom Pollen, Chairman and Chief Executive Officer and President of BD. “We have made commitments that build on our purpose to advance the world of healthcare, and true to our culture, we are delivering on those commitments and positioning BD for sustainable growth and resilience.”
The report includes the first performance metrics and progress towards the company’s ESG 2030+ commitments, which were unveiled in October 2021. Focusing on the key areas where the company seeks to create meaningful and measurable change over the next decade, highlights and accomplishments from this year’s report include:
- Climate change – BD joined the Race to Zero, committing to achieve Scope 1, 2 and 3 greenhouse gas reduction targets under 1.5⁰C emissions scenarios to achieve science-based net zero emissions by 2050. The company continues to make progress toward its 25% energy goal by 2030 (compared to a 2019 baseline, normalized to cost of goods sold), achieving a 14% energy reduction in fiscal 2021, in addition to increasing its investments in on-site renewable energy. Currently, 13 BD sites derive 100% of their electricity from renewable sources.
- Product impact – BD recently launched a Sustainable Medical Technology Institute to help further reduce the environmental impact of the company’s portfolio, establish sustainable design standards for products, and identify more sustainable sterilization technologies. The company continues to manage the end-of-life disposal of BD Pyxis™ portfolio products, resulting in 20,771 units processed in fiscal year 2021, which equates to 1,855.15 metric tons of material that have been refurbished, reused or recycled, without disposal of materials. through the landfill.
- Responsible Supply Chain – The company spent $565 million with suppliers of companies belonging to various interests and $1 billion with small business suppliers, impacting 2,766 suppliers in total. This reflects a 33% average increase in supplier diversity spending over fiscal year 2020, across all diverse ownership and small business supplier categories.
- Healthy Workforce and Communities – The company’s global pay equity assessment for fiscal year 2021 of associates in 57 countries showed female employees earning 98 cents for each $1 won by associated men (99 cents in the United States), progressing towards the company’s commitment to achieve 100% pay equity. [The results showed that BD associates are paid fairly and equitably, and that on average, both women and men are paid within a range that would be expected after controlling for legitimate differentiating factors.] To support the community and human health, BD has donated more than $24 million in cash and commodities worldwide to eligible nonprofit organizations to support resilient communities and expand healthcare access and equity. This included $4.1 million in cash and product donations to free and charitable clinics and community centers in the United States, such contributions totaling $34.5 million since 2009.
- Transparency – BD released its first Inclusion, Diversity and Equity report and its second Cybersecurity report. The company earned a score of 100% on the Center for Political Accountability’s 2021 Corporate Political Disclosure and Accountability Index, and was named one of America’s Most Responsible Companies and one of of America’s Most Trusted Companies by Newsweek. The ESG report also includes information in accordance with the guidelines of the October 2021 report “Implementation of the recommendations of the working group on climate-related financial information.”
“We have worked with a wide range of stakeholders to drive our strategy and track progress over the past year, which includes launching a sustainable medical technology institute, participating in the race to zero, setting science-based targets to help address the worst effects of climate change, and increasing renewable energy sources,” said Maureen Mazurek, Vice President of Sustainability, Environment, Health & Safety and Product Stewardship at BD. “We have developed our ESG 2030+ commitments by focusing our organization where we can have the greatest impact on our industry, our people, our communities and our planet today. We know this work can have a lasting positive impact, which is why we will continue to challenge ourselves to find opportunities for growth, improvement, and doing the right thing.“
View the full fiscal 2021 environmental, social and governance report on BD.com.
comics is one of the world’s largest global medical technology companies and advances the world of healthcare by improving medical discovery, diagnostics and care delivery. The company supports heroes on the front lines healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. comics and its 75,000 employees have a passion and commitment to help improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease, and advance capabilities researchers to develop the next generation of diagnostics and therapies. comics operates in virtually every country and partners with organizations around the world to address some of the world’s toughest health issues. By working closely with customers, comics can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information on comicsplease visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
This press release contains certain forward-looking statements within the meaning of the federal securities laws regarding BD’s business, strategy, goals, commitments and objectives. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed, projected, anticipated or implied by such statements. All statements, other than statements of historical fact, may be forward-looking statements. Certain forward-looking statements can be identified by the use of words such as “plan”, “expect”, “believe”, “intend”, “will”, “may”, “anticipate”, estimate ”, “target”, and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and growth strategy, future product development, regulatory approvals, competitive position , initiatives and spending on sustainable development. Forward-looking statements are, and will be, based on management’s then-current beliefs and assumptions regarding future events, developments and operating performance, and speak only as of their dates.
Statements regarding BD’s goals, commitments and objectives may include statistics or measurements based on estimates and assumptions under developing standards that may change in the future. These goals and commitments are not intended to be promises or guarantees and actual results may differ, possibly significantly. It is not possible to predict or identify all of these risks and uncertainties, many of which are beyond BD’s control, including, but not limited to, challenges relating to economic, competitive, governmental and technological factors affecting operations. , BD’s markets and products, and other factors listed in BD’s 2021 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. BD expressly disclaims any undertaking to update or revise any forward-looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.
SVP, Head of Investor Relations
COMIC SOURCE (Becton, Dickinson and Company)